| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003581599 |
| P356 | DOI | 10.1054/BJOC.2001.2175 |
| P932 | PMC publication ID | 2364004 |
| P698 | PubMed publication ID | 11747337 |
| P5875 | ResearchGate publication ID | 11610323 |
| P2093 | author name string | M Stewart | |
| M G Dunlop | |||
| P G Johnston | |||
| D I Jodrell | |||
| D B Longley | |||
| A Leitch | |||
| A M Lessells | |||
| N A Wong | |||
| L Brett | |||
| P2860 | cites work | Thymidylate synthase is localized to the nuclear periphery in the yeast Saccharomyces cerevisiae | Q27937141 |
| 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer | Q28359288 | ||
| Intracellular location of thymidylate synthase and its state of phosphorylation | Q28580813 | ||
| Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex | Q28584078 | ||
| Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer | Q33930691 | ||
| The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. | Q50875167 | ||
| p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. | Q51035952 | ||
| Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy | Q57567897 | ||
| Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells | Q68463821 | ||
| Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies | Q69898972 | ||
| Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors | Q72611029 | ||
| Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil | Q72729387 | ||
| Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil | Q73393205 | ||
| Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer | Q73605081 | ||
| Clonal growth of colorectal-carcinoma cell lines transplanted to nude mice | Q73899306 | ||
| Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer | Q73967003 | ||
| Immunohistochemical determination of thymidylate synthase in colorectal cancer--methodological studies | Q74201989 | ||
| The utility of the proliferative index in pretreatment biopsy specimens of esophageal squamous cell carcinoma | Q74594482 | ||
| DNA mismatch repair and colorectal cancer | Q77129031 | ||
| Immunohistochemical investigation of thymidylate synthase in cervical cancer | Q77432079 | ||
| 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics | Q77529134 | ||
| Prognosis and prediction of response in breast cancer: the current role of the main biological markers | Q77683176 | ||
| Identification of in vivo target RNA sequences bound by thymidylate synthase | Q34608316 | ||
| Mismatch repair proficiency and in vitro response to 5-fluorouracil | Q35129256 | ||
| Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy | Q36116454 | ||
| Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients | Q36621223 | ||
| Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy | Q38466842 | ||
| Significance of angiogenesis in tumour progression and metastasis | Q40423643 | ||
| Thymidylate synthase and drug resistance | Q40423844 | ||
| A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance | Q40872945 | ||
| Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein | Q41097416 | ||
| Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue | Q41652928 | ||
| Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. | Q41731908 | ||
| The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer | Q43960974 | ||
| Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial | Q45961645 | ||
| Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction | Q46100135 | ||
| p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. | Q46365618 | ||
| p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. | Q46465176 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal carcinoma | Q25493920 |
| P304 | page(s) | 1937-43 | |
| P577 | publication date | 2001-12-14 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma | |
| P478 | volume | 85 |
| Q90687449 | A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model |
| Q36772028 | Cancer of the colon and rectum: potential effects of sex-age interactions on incidence and outcome |
| Q39644517 | Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer |
| Q46160850 | Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma |
| Q36474351 | Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine |
| Q92391312 | Deoxyuracil in DNA and disease: Genomic signal or managed situation? |
| Q89336851 | Dietary Uridine Decreases Tumorigenesis in the ApcMin/+ Model of Intestinal Cancer |
| Q35773077 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. |
| Q57004900 | Evaluation of thymidylate synthase protein expression by Western blotting and immunohistochemistry on human colon carcinoma xenografts in nude mice |
| Q46356485 | Folate-mediated one-carbon metabolism |
| Q36205831 | Genetic factors influencing pyrimidine-antagonist chemotherapy. |
| Q39189050 | Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells |
| Q40409889 | Nuclear expression of thymidylate synthase in colorectal cancer cell lines and clinical samples |
| Q47794376 | Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor |
| Q33320579 | Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy |
| Q36646148 | Role of biological markers in the clinical outcome of colon cancer |
| Q36610474 | Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. |
| Q45073488 | Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients |
| Q39017134 | Targeting nuclear thymidylate biosynthesis |
| Q28274343 | The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer |
| Q54394304 | Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy. |
| Q37983841 | Trafficking of intracellular folates |
Search more.